dorsal/arxiv
View SchemaDeveloping Predictive and Robust Radiomics Models for Chemotherapy Response in High-Grade Serous Ovarian Carcinoma
| Authors | Sepideh Hatamikia, Geevarghese George, Florian Schwarzhans, Amirreza Mahbod, Marika AV Reinius, Ali Abbasian Ardakani, Mercedes Jimenez-Linan, Satish Viswanath, Mireia Crispin-Ortuzar, Lorena Escudero Sanchez, Evis Sala, James D Brenton, Ramona Woitek |
|---|---|
| Categories | |
| ArXiv ID | 2601.08455vv1 |
| URL | https://arxiv.org/abs/2601.08455 |
| License | http://arxiv.org/licenses/nonexclusive-distrib/1.0/ |
Abstract
Objectives: High-grade serous ovarian carcinoma (HGSOC) is typically diagnosed at an advanced stage with extensive peritoneal metastases, making treatment challenging. Neoadjuvant chemotherapy (NACT) is often used to reduce tumor burden before surgery, but about 40% of patients show limited response. Radiomics, combined with machine learning (ML), offers a promising non-invasive method for predicting NACT response by analyzing computed tomography (CT) imaging data. This study aimed to improve response prediction in HGSOC patients undergoing NACT by integration different feature selection methods. Materials and methods: A framework for selecting robust radiomics features was introduced by employing an automated randomisation algorithm to mimic inter-observer variability, ensuring a balance between feature robustness and prediction accuracy. Four response metrics were used: chemotherapy response score (CRS), RECIST, volume reduction (VolR), and diameter reduction (DiaR). Lesions in different anatomical sites were studied. Pre- and post-NACT CT scans were used for feature extraction and model training on one cohort, and an independent cohort was used for external testing. Results: The best prediction performance was achieved using all lesions combined for VolR prediction, with an AUC of 0.83. Omental lesions provided the best results for CRS prediction (AUC 0.77), while pelvic lesions performed best for DiaR (AUC 0.76). Conclusion: The integration of robustness into the feature selection processes ensures the development of reliable models and thus facilitates the implementation of the radiomics models in clinical applications for HGSOC patients. Future work should explore further applications of radiomics in ovarian cancer, particularly in real-time clinical settings.
{
"annotation_id": "94786b30-0938-46e3-90fa-122b23f32241",
"date_created": "2026-02-17T05:53:15.636000Z",
"date_modified": "2026-02-17T05:53:15.636000Z",
"file_hash": "2dd07e09931188e60ac413bc0fe1da773e274df4ec4eed7d26b0d16fd7d5cdd1",
"private": false,
"record": {
"abstract": "Objectives: High-grade serous ovarian carcinoma (HGSOC) is typically diagnosed at an advanced stage with extensive peritoneal metastases, making treatment challenging. Neoadjuvant chemotherapy (NACT) is often used to reduce tumor burden before surgery, but about 40% of patients show limited response. Radiomics, combined with machine learning (ML), offers a promising non-invasive method for predicting NACT response by analyzing computed tomography (CT) imaging data. This study aimed to improve response prediction in HGSOC patients undergoing NACT by integration different feature selection methods. Materials and methods: A framework for selecting robust radiomics features was introduced by employing an automated randomisation algorithm to mimic inter-observer variability, ensuring a balance between feature robustness and prediction accuracy. Four response metrics were used: chemotherapy response score (CRS), RECIST, volume reduction (VolR), and diameter reduction (DiaR). Lesions in different anatomical sites were studied. Pre- and post-NACT CT scans were used for feature extraction and model training on one cohort, and an independent cohort was used for external testing. Results: The best prediction performance was achieved using all lesions combined for VolR prediction, with an AUC of 0.83. Omental lesions provided the best results for CRS prediction (AUC 0.77), while pelvic lesions performed best for DiaR (AUC 0.76). Conclusion: The integration of robustness into the feature selection processes ensures the development of reliable models and thus facilitates the implementation of the radiomics models in clinical applications for HGSOC patients. Future work should explore further applications of radiomics in ovarian cancer, particularly in real-time clinical settings.",
"arxiv_id": "2601.08455",
"authors": [
"Sepideh Hatamikia",
"Geevarghese George",
"Florian Schwarzhans",
"Amirreza Mahbod",
"Marika AV Reinius",
"Ali Abbasian Ardakani",
"Mercedes Jimenez-Linan",
"Satish Viswanath",
"Mireia Crispin-Ortuzar",
"Lorena Escudero Sanchez",
"Evis Sala",
"James D Brenton",
"Ramona Woitek"
],
"categories": [
"cs.CV"
],
"license": "http://arxiv.org/licenses/nonexclusive-distrib/1.0/",
"title": "Developing Predictive and Robust Radiomics Models for Chemotherapy Response in High-Grade Serous Ovarian Carcinoma",
"url": "https://arxiv.org/abs/2601.08455",
"version": "v1"
},
"schema_id": "dorsal/arxiv",
"source": {
"execution_id": "cbe0597f-e2ba-4475-815d-30ddacb09697",
"id": "arXiv Dataset",
"type": "Model",
"variant": "snapshot-2026-01-17",
"version": "0.1.0"
},
"user_id": 1000002
}